The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches
Immunity, Inflammation and Disease · 2023
DOI: 10.1002/iid3.1022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, 2023. Verfasst von Mingwei Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Qinzhou First People's Hospital, Qinzhou, China. Hauptthemen laut MEDLINE: Glioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Low‐grade gliomas (LGGs) are currently considered a premalignant condition for high‐grade gliomas (HGGs) and are characterized by a relatively intact immune system. Immunotherapeutic modalities may offer a safe and effective treatment option for these patients. However , the CD2–CD58 axis, an important component of the immunological synapse, remains unknown in LGG.
Methods
RNA‐seq data from TCGA databases were analyzed. Immune cell infiltration was determined using a single‐sample gene set enrichment analysis (ssGSEA) based on integrated immune gene sets from published studies. Kaplan–Meier survival analysis, univariate and multivariate logistic analysis, and the ESTIMATE algorithm were employed to evaluate the impact of the CD2–CD58 axis on adult LGG patients.
Results
The expression of the CD2–CD58 axis was found to be elevated with increasing of WHO grade ( p < .05). Uni‐ and multi‐variable logistic analysis demonstrated that age, WHO grade, and CD58 levels were associated with poor prognosis in LGG patients with ( p < .01). MetaSape pathways analysis revealed the involvement of CD58 in regulating T cell activation, leukocyte‐mediated immunity, and the positive regulation of cell activation in WHO grade II and III. CD58 expression correlated with infiltrations of CD4+ lymphocytes, NK cells, and macrophages cells. The ESTIMATE algorithm indicated that patients with high CD58 expression had significantly higher immune scores compared with low CD58 expression in WHO grade II/III, but no statistical difference was observed in WHO grade IV ( p < .05). Furthermore, correlation analysis demonstrated the significant association between CD58 and CD274 ( r = 0.581, p < .001), HAVCR2 ( r = 0.58i7, p < .001), and LGALS9 ( r = 0.566, p < .001). Immunohistochemical staining further confirmed the relationship of CD58, HAVCR2, WHO grade, and prognosis in grade II and III patients.
Conclusion
Overall, our findings highlight the significant association between the CD2–CD58 axis and poor survival in LGG patients. High CD58 expression is implicated in T cell‐mediated immune responses as an immunosuppressive factor and affect inhibitory immune checkpoint genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qinzhou First People's Hospital, Qinzhou, China.
- Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Gao Hua
Zitieren
APA
Wu, M., Chen, Y., Hua, G., & Chunhui, L. (2023). The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches. Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1022
Vancouver
Wu M, Chen Y, Hua G, Chunhui L. The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches. Immunity, Inflammation and Disease. 2023. doi:10.1002/iid3.1022
BibTeX
@article{Wu2023,
author = {Wu, Mingwei and Chen, Yiyuan and Hua, Gao and Chunhui, Liu},
title = {The CD2–CD58 axis: A novel marker predicting poor prognosis in patients with low‐grade gliomas and potential therapeutic approaches},
journal = {Immunity, Inflammation and Disease},
year = {2023},
doi = {10.1002/iid3.1022}
}
EUVIMED